• Piero Gentile, Gabriella Masciocco, Matteo Palazzini, Andrea Tedeschi, Giacomo Ruzzenenti, Nicolina Conti, Luciana D'Angelo, Grazia Foti, Enrico Perna, Alessandro Verde, Enrico Ammirati, Gianfranco Sinagra, Fabrizio Oliva, and Andrea Garascia.
• De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy.
• Eur. J. Intern. Med. 2023 Oct 1; 116: 657165-71.

IntroductionIntravenous inotropic support represents an important therapeutic option in advanced heart failure (HF) as bridge to heart transplantation, bridge to mechanical circulatory support, bridge to candidacy or as palliative therapy. Nevertheless, evidence regarding risks and benefits of its use is lacking.Methodswe conducted a retrospective single center study, analysing the effect of inotropic therapies in an outpatient cohort, evaluating the burden of hospitalizations, the improvement in quality of life, the incidence of adverse events and the evolution of organ damage.Resultstwenty-seven patients with advanced HF were treated in our Day Hospital service from 2014 to 2021. Nine patients were treated as bridge to heart transplant while eighteen as palliation. Comparing data regarding the year before and after the beginning of inotropic infusion, we observed a reduction of hospitalization (46 vs 25, p<0,001), an improvement of natriuretic peptides, renal and hepatic function since the first month (p<0,001) and a better quality of life in 53% of the population treated. Two hospitalizations for arrhythmias and seven hospitalizations for catheter-related complications were registered.Conclusionsin a selected population of advanced HF patients, continuous home inotropic infusion were able to reduce hospitalizations, improving end organ damage and quality of life. We provide a practical guidance on starting and maintaining home inotropic infusion while monitoring a challenging group of patients.Copyright © 2023. Published by Elsevier B.V.

12 keywords...

hide…